We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 46 of 64 for:    lyme

Human Anaplasmosis in Eastern France

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01013636
Recruitment Status : Unknown
Verified August 2011 by University Hospital, Strasbourg, France.
Recruitment status was:  Recruiting
First Posted : November 16, 2009
Last Update Posted : August 30, 2011
Sponsor:
Information provided by:

November 10, 2009
November 16, 2009
August 30, 2011
November 2009
April 2012   (Final data collection date for primary outcome measure)
Risk factor, clinical and biological markers of infection for patients with Anaplasma antibody seroconversion [ Time Frame: 6 weeks ]
Same as current
Complete list of historical versions of study NCT01013636 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Human Anaplasmosis in Eastern France
Epidemiology and Clinical Presentation of Human Anaplasmosis in Eastern France
Anaplasmosis is a tick-borne transmitted infection. Its clinical expression include fever, cytopenia and hepatitis.This infection was initially described in United States. In Europe, its epidemiology is not well known. Some isolated cases have been diagnosed in several country, were the tick Ixodes ricinus is known to transmitted another infection :the Lyme borreliosis.The purpose of our study is to look systematically for Anaplasmosis, in patient living in Eastern France, and presenting with compatible clinical symptoms using a new diagnosis tool : PCR in blood samples. So we will have new data about epidemiology in our country and the clinical symptoms that are associated with Anaplasmosis.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
whole blood
Non-Probability Sample
patients with Anaplasma phagocytophilia
  • Anaplasmosis
  • Tick-borne Disease
  • Ehrlichia
Procedure: Blood sampling
  • Anaplasma diagnosis test : serology and PCR
  • If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days
Anaplasma
Intervention: Procedure: Blood sampling
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
300
Not Provided
April 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • patient with at least one of following symptoms : fever or muscular pain or articular pain or respiratory signs or neurological signs or meningitis or erythema occurring during the three weeks after a tick bite-
  • Or
  • patient with fever with at least one of following criteria : thrombocytopenia, leucopenia, hepatitis, without any other cause that can explain these abnormalities.
  • Or
  • patient with tick-borne encephalitis, or primary stage Lyme borreliosis

Exclusion Criteria:

  • children less that 10 years
  • pregnancy
  • patients with an other diagnosis that can explain clinical symptoms or biological abnormalities
  • antibiotherapy with cyclins during the days before inclusion
Sexes Eligible for Study: All
10 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01013636
3960
No
Not Provided
Not Provided
Christine GEILLER/ Directeur de la recherche clinique et des innovations, University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: YVES HANSMANN, MD Service des Maladies Infectieuses et Tropicales Hôpitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
August 2011